BioCentury | Jun 7, 2018
Finance

Deerfield goes to school

...translation via Bridge Medicines -- its first foray into funding academic discoveries at the institutional level. Bridge Medicines...
...Companies and Institutions Mentioned Bay City Capital, San Francisco, Calif. Bayer AG (Xetra:BAYN), Leverkusen, Germany Bridge Medicines...
...S. “Virtually biotechs.” BioCentury Innovations (2016) Amran Gowani, Senior Editor, Finance & Business Development Bay City Capital Bayer AG Bridge Medicines Broad...
BioCentury | Apr 3, 2018
Company News

Management tracks: Abeona, Dermavant, Assembly

...hired Ann Rhoads as CFO. Rhoads was EVP and CFO at Zogenix Inc. (NASDAQ:ZGNX). Incubator Bridge Medicines...
BioCentury | Oct 19, 2017
Finance

Broad umbrella

...support from ShangPharm; Scripps and Calibr retain rights, SPII receives "significant share" of future value Bridge Medicines...
...Bay City Capital Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) Undisclosed Tri-I TDI projects graduate into Bridge Medicines...
...its first foray into financing translational research at the institutional level via the formation of Bridge Medicines...
BioCentury | Apr 28, 2017
Finance

Hatching VC incubators

...2015 Sofinnova BiovelocITA Translate Italy's academic science Virtual None 1 2016 Deerfield; Bay City Capital Bridge Medicines...
BioCentury | Nov 4, 2016
Company News

Takeda, MSKCC, Rockefeller and Weill deal

...Memorial Sloan Kettering Cancer Center, Rockefeller University and Weill Cornell Medical College launched Bridge Medicines, a drug...
...treatments and therapies. The partners said candidates developed at Tri-I TDI can now "graduate" to Bridge Medicines...
...in creating scientific and business development plans for the projects. The partners said projects at Bridge Medicines...
BioCentury | Nov 2, 2016
Company News

N.Y. research group, Takeda launch newco Bridge

...Memorial Sloan Kettering Cancer Center , Rockefeller University and Weill Cornell Medical College launched Bridge Medicines, a...
...treatments and therapies. The partners said candidates developed at Tri-I TDI can now "graduate" to Bridge Medicines...
...in creating scientific and business development plans for the projects. The partners said projects at Bridge Medicines...
Items per page:
1 - 6 of 6
BioCentury | Jun 7, 2018
Finance

Deerfield goes to school

...translation via Bridge Medicines -- its first foray into funding academic discoveries at the institutional level. Bridge Medicines...
...Companies and Institutions Mentioned Bay City Capital, San Francisco, Calif. Bayer AG (Xetra:BAYN), Leverkusen, Germany Bridge Medicines...
...S. “Virtually biotechs.” BioCentury Innovations (2016) Amran Gowani, Senior Editor, Finance & Business Development Bay City Capital Bayer AG Bridge Medicines Broad...
BioCentury | Apr 3, 2018
Company News

Management tracks: Abeona, Dermavant, Assembly

...hired Ann Rhoads as CFO. Rhoads was EVP and CFO at Zogenix Inc. (NASDAQ:ZGNX). Incubator Bridge Medicines...
BioCentury | Oct 19, 2017
Finance

Broad umbrella

...support from ShangPharm; Scripps and Calibr retain rights, SPII receives "significant share" of future value Bridge Medicines...
...Bay City Capital Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) Undisclosed Tri-I TDI projects graduate into Bridge Medicines...
...its first foray into financing translational research at the institutional level via the formation of Bridge Medicines...
BioCentury | Apr 28, 2017
Finance

Hatching VC incubators

...2015 Sofinnova BiovelocITA Translate Italy's academic science Virtual None 1 2016 Deerfield; Bay City Capital Bridge Medicines...
BioCentury | Nov 4, 2016
Company News

Takeda, MSKCC, Rockefeller and Weill deal

...Memorial Sloan Kettering Cancer Center, Rockefeller University and Weill Cornell Medical College launched Bridge Medicines, a drug...
...treatments and therapies. The partners said candidates developed at Tri-I TDI can now "graduate" to Bridge Medicines...
...in creating scientific and business development plans for the projects. The partners said projects at Bridge Medicines...
BioCentury | Nov 2, 2016
Company News

N.Y. research group, Takeda launch newco Bridge

...Memorial Sloan Kettering Cancer Center , Rockefeller University and Weill Cornell Medical College launched Bridge Medicines, a...
...treatments and therapies. The partners said candidates developed at Tri-I TDI can now "graduate" to Bridge Medicines...
...in creating scientific and business development plans for the projects. The partners said projects at Bridge Medicines...
Items per page:
1 - 6 of 6